Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Belite Bio, IncNASDAQ: BLTE
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$36.91M, compared with -$21.69M a year earlier. Trailing-twelve-month EBITDA was -$129.44M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -116.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$36.91M-5.7% QoQ
- Last fiscal yearDec 2025
- -$77.15M-116.3% YoY
- LTMSep 2026
- -$129.44M-116.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -70.2% | +100.0% | +170.2 pp |
| 1 year | -116.3% | +100.0% | +216.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (77.15M) USD
- Year-over-year change
- -116.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (77.15M) | -116.3% |
| FY2024 | 2024-12-31 | (35.67M) | -14.3% |
| FY2023 | 2023-12-31 | (31.2M) | -150.9% |
| FY2022 | 2022-12-31 | (12.43M) | -29.0% |
| FY2021 | 2021-12-31 | (9.64M) | — |
EBITDA vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Sep 2026 EBITDA of -$129.44M is the 4th highest of the 6 companies compared; the peer median is -$104.73M.
- Its year-over-year change of -116.5% is the 5th highest of 6, against a peer median of -19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.08M | +36.5% | — | — |
| LTM Mar 2026 | -$64.18M | -19.1% | — | 1437.5% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$104.73M | -226.0% | — | 874.0% |
BLTEBelite Bio, Inc | LTM Sep 2026 | -$129.44M | -116.5% | — | — |
| LTM Sep 2026 | -$225.15M | -18.0% | — | — | |
| LTM Mar 2026 | -$260.06M | -79.4% | — | 3415.1% | |
| Peer median (excluding BLTE) | -$104.73M | -19.1% | — | 1437.5% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Selling, General & Admin | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Operating Expenses | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| EBITDA | (9.64M) | (12.43M) | (31.2M) | (35.67M) | (77.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.8M) | (12.82M) | (31.67M) | (40M) | (84.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5K | 23K | 74K | 3.74M | 0 |
| Interest Expense | 0 | 16K | 25K | 20K | 0 |
| Other Income / Expenses | 131K | 173K | 45K | 3.86M | 6.6M |
| Income Before Tax | (9.67M) | (12.65M) | (31.62M) | (36.14M) | (77.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 9K | 6K | 0 |
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| EPS (Diluted) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| Weighted Avg Shares | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
| Weighted Avg Shares (Diluted) | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.